New Pill Offers Hope Against Aggressive Ovarian Cancer

A new drug, relacorilant, typically prescribed for Cushing's syndrome, has shown significant promise in extending the lives of women diagnosed with aggressive ovarian cancer. Clinical trials presented at the Society of Gynecologic Oncology's annual meeting in San Juan revealed that patients treated with relacorilant plus the chemotherapy drug nab-paclitaxel lived an average of 16 months, a substantial improvement over the 11.9 months experienced by those on standard treatment alone. This represents a 35% reduction in the risk of death, positioning the combination as a potential new standard of care.

The trial, which involved 381 patients with platinum-resistant ovarian cancer, also highlighted that relacorilant has fewer side effects and can be taken at home, offering a more convenient option for patients. The U.S. Food and Drug Administration (FDA) granted approval for this new therapy combination late last month for patients who have undergone at least one prior treatment round. However, in the UK, the National Institute for Health and Care Excellence (NICE) has not yet approved relacorilant. Ovarian cancer, the sixth most common cancer in the UK, tragically claims around 4,000 lives annually, often due to late diagnosis. Early detection significantly improves survival rates, with 93% of women diagnosed at the earliest stage living five years or more, compared to only 13% diagnosed at stage four.